title: Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC).
  
  
  METHODS
  In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. OBJECTIVE response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models.
  
  
  RESULTS
  Treatment with bevacizumab and chemotherapy was effective and tolerable. Univariate analysis showed that PFS and OS were significantly associated with the Eastern Cooperative Oncology Group performance status (ECOG- PS) score, duration of bevacizumab exposure, and whether chemotherapy was continued after discontinuation of bevacizumab treatment. A multivariate analysis showed that the duration of bevacizumab exposure and whether chemotherapy was continued after discontinuation of bevacizumab were independent prognostic factors for PFS and OS.
  
  
  CONCLUSIONS
  In Chinese mCRC population, the shorter the duration of exposure to bevacizumab and chemotherapy, the worse the prognosis is.
authors.affiliation: Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China * E-mail : zjszlyy_zlm@163.com.
authors.forename: Li-Ming
authors.initials: LM
authors.lastname: Zhu
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Zhao
authors.forename: Hai-Xing
authors.initials: HX
authors.lastname: Ju
authors.forename: Lu-Ying
authors.initials: LY
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.forename: Bi-Xia
authors.initials: BX
authors.lastname: Liu
authors.forename: Qi
authors.initials: Q
authors.lastname: Xu
authors.forename: Cong
authors.initials: C
authors.lastname: Luo
authors.forename: Jie-Er
authors.initials: JE
authors.lastname: Ying
authors.forename: Yun-Shan
authors.initials: YS
authors.lastname: Yang
authors.forename: Hai-Jun
authors.initials: HJ
authors.lastname: Zhong
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002681:China; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin